LyondellBasell is in solid financial health. Management reported a net debt/adjusted EBITDA ratio of 1.8 times as of Dec. 31, 2024. We expect the leverage ratio will remain healthy over time as the ...

This allows Dow to manufacture at a significant cost advantage to marginal cost producers that rely on higher-cost crude oil-based feedstocks to make the same products. Dow’s commodity chemicals are ...

Wizz Air Holdings reported strong revenue growth in Q3 Fiscal 2025 despite significant challenges, including a notable unrealized foreign exchange loss. The company revised its full-year guidance ...

Caixabank SA (BME:CABK) reported robust financial results for the fourth quarter of 2024, highlighting a 20% year-over-year ...

UnitedHealth UNH-0.29%decrease; red down pointing triangle Group shares dropped after it reported higher medical costs in the fourth quarter, despite earnings that beat analysts’ expectations.

I rate Westlake Chemical Partners a hold due to mixed financial performance and a plateauing price chart ... cost environment or a lower marginal growth in cost relative to marginal revenue ...

UnitedHealth Group Inc. shares fell after elevated medical costs persisted in the fourth quarter and revenue missed estimates. The stock dropped as much as 5.2% in early trading Thursday ...

(Bloomberg) -- UnitedHealth Group Inc. shares fell after elevated medical costs persisted in the fourth quarter and revenue missed estimates. The biggest US health insurer’s stock lost as much ...

UnitedHealth brought in a record $400.3 billion in revenue in 2024 despite a string ... Still, when excluding the cyberattack costs (and other factors UnitedHealth believes aren’t representative ...

Medical costs in the fourth quarter came in above ... intact," said Morningstar analyst Julie Utterback. Fourth-quarter revenue was $100.81 billion, below estimates of $101.76 billion, hurt ...

However, not all financial products are worth your investment. Some carry high fees, hidden risks, or offer poor returns, making them more harmful than beneficial. In this blog, we will explore ...

(OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary XHANCE (fluticasone propionate) net product revenue of $22.4 million for the ...